Mirapex Eye Study


back to Current Trials

A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's Disease patients

This study target patients with early stage Parkinson's Disease (PD) who is requiring treatment with dopamine agonists (Mirapex, Requip). If already being treated and it's for less than 6 months, you are still allowed to participate.This is a two year study to determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR (Mirapex) versus ropinirole (Requip). This is an open-label study meaning that you will receive treatment, no placebo involved. Screening will involve a visit to the ophthalmologist to rule out any current retinal disease, a cardiogram (EKG), blood work and various evaluations by the neurologist before participation in the trial.

If you are interested in knowing more about this clinical trial, please contact:

Angel Figueroa
Research Worker
212.305.6121
af2161@columbia.edu

Anne Tam, CCRC
Clinical Trials Coordinator
212.305.6121
atam@neuro.columbia.edu